Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

BMB. 2022; 7(2): 130-136


Predictive factors of complete tumor response to first line chemotherapy in patients with extensive-stage small cell lung cancer

Eyyüp Çavdar, Yakup İriağaç, Abdullah Sakin, Erdoğan Selçuk Şeber.




Abstract

Objective: We aimed to investigate the factors affecting the complete response(CR) to treatment and the effect of treatment response level on survival in patients with extensive stage small cell lung cancer (ES-SCLC) who received a combination of cisplatin and etoposide as first-line therapy.
Method: This retrospective analysis included 140 ES-SCLC patients, who were followed in an oncology clinic. Patients were divided into two groups as CR and non-CR according to radiological evaluation after first line chemotherapy. Clinical and demographical characteristics, pre-treatment hemogram parameters were obtained from archive files and compared between CR and non-CR patients.
Results: While CR was seen in 34 (24.3%) of all patients after the first line chemotherapy, 106 (75.7%) patient were in the non-CR group. On univariate analysis, predictors for complete response to treatment were, absence of brain metastasis , receiving 6 chemotherapy cycles and good performance status (p

Key words: Small cell lung cancer, survival prognosis, complete response, chemotherapy






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.